The role and efficacy of Sacituzumab govitecan

Sacituzumab govitecan is an antibody-drug conjugate developed to treat solid tumors, including breast cancer and urothelial cancer. Gosatuzumab was developed through the site-specific conjugation of the active metabolite of irinotecan, SN-38 (govitecan), with a humanized monoclonal antibody (hRS7) against trophoblast surface antigen-2 (Trop-2). Trop-2 is overexpressed in many solid tumors and has limited expression in normal tissues. Trop-2 plays a role in tumorigenesis and is associated with poor prognosis in several cancers, including breast cancer.

Intravenous gosatuzumab received accelerated approval in the United States on April 22, 2020, for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior treatments for metastatic disease. The approval is based on results from Phase I/II trials; continued approval will require demonstration of clinical benefit in confirmatory Phase III trials. The recommended dose of gosatuzumab is 10 mg/kg on days 1 and 8 of a consecutive 21-day treatment cycle until disease progression or unacceptable toxicity occurs. In the United States, prescribing information for gosatuzumab carries a boxed warning for neutropenia and diarrhea.

Gosatuzumab The original drug has been launched in China, but it has not yet been included in the medical insurance. The price of a 100mg bottle may be around 10,000 yuan, which is relatively expensive. Gosatuzumab Original drug marketed overseas has three versions: European version, American version, and Singapore version. SpecificationsThe price of each 100 mg bottle may be around RMB 10,000-35,000 (the price may fluctuate due to exchange rates). The ingredients of gosatuzumab sold domestically and abroad are basically the same. There is currently no generic version of gosatuzumab available on the market. For specific prices and drug information, please consult your medical consultant.